Wegovy Pill Surge Positions Novo Nordisk to Reclaim Ground in GLP-1 Race

Novo Nordisk’s newly introduced oral version of Wegovy is registering prescription volumes well above internal projections, reshaping the competitive dynamic in the fast-growing market for GLP-1 weight-management therapies. The Danish drugmaker reported 1.3 million prescriptions for the pill during the first quarter of 2026 and disclosed that the total had climbed to 2 million by the time first-quarter earnings were released one month later.

The brisk uptake comes less than two years after Novo Nordisk fell behind Eli Lilly in the same therapeutic category. Eli Lilly’s injectable GLP-1 products—Mounjaro for diabetes and its weight-loss variant Zepbound—delivered stronger efficacy data, enabling the U.S. company to seize market share while Novo Nordisk struggled to supply its injectable Wegovy formulation. Investor sentiment shifted quickly: over the past three years Novo Nordisk shares retreated roughly 40 percent, whereas Eli Lilly stock advanced more than 150 percent.

The oral launch has altered expectations for Novo Nordisk’s near-term performance. Although management had cautioned that 2026 would be challenging because of Indian patent expirations and lower U.S. prices, the early success of the pill suggests volume growth could counter those headwinds. The company’s guidance indicates that rising prescription counts are likely to offset price concessions over time, a scenario reinforced by the first-quarter prescription surge.

The Shift From Injections to Pills

GLP-1 agonists, originally approved for type 2 diabetes, have become a key resource for medically supervised weight reduction. Many patients, however, prefer oral administration to injections, a preference that expands the prospective customer base. By converting the active ingredient semaglutide into an orally available format under the Wegovy brand, Novo Nordisk addressed a major barrier to adoption and opened an avenue to regain lost ground.

Internal data show that the pill’s uptake is supplementing, rather than displacing, demand for the injectable form. That pattern implies the total addressable market is widening instead of merely shifting between product formats. If sustained, this trend could extend the product’s commercial life cycle even as pricing pressure intensifies in established markets.

Competitive Landscape

Eli Lilly remains the category leader in unit sales and efficacy benchmarks, but Novo Nordisk’s rapid prescription growth signals that brand recognition and route-of-administration convenience continue to influence physician and patient choices. Industry observers anticipate that both companies will work to diversify dosage forms and expand manufacturing capacity to keep pace with global demand.

Rivalry is expected to remain intense. Both companies are conducting trials aimed at earlier intervention for obesity-related comorbidities, pediatric indications, and combination therapies. The U.S. Food and Drug Administration, which maintains a publicly accessible database of approved GLP-1 agents, lists several additional candidates in late-stage development, underscoring ongoing innovation pressure across the segment. Interested readers can review the current roster of authorized products on the FDA’s official website.

Regional Pressures and Opportunities

While momentum in North America and Europe is strong, Novo Nordisk faces specific challenges in two important regions:

Imagem: Internet

• India: Patent protection for Wegovy lapsed early in 2026, opening the market to lower-cost competitors. Management expects revenue in India to decline but believes global volume will offset the regional setback.
• United States: In late 2025 the company agreed to price reductions for Wegovy as part of broader negotiations with pharmacy benefit managers and government payers. Lower net pricing is already reflected in 2026 guidance, and higher prescription volume is projected to mitigate the impact.

Collectively, these factors paint a mixed but improving outlook. The pill’s rapid adoption provides a concrete data point indicating that volume elasticity remains robust despite contractual price cuts. If that elasticity persists, revenue erosion from competitive entry and regional pricing adjustments could be less severe than initially forecast.

Share-Price Performance and Dividend Considerations

The disparity between the two companies’ recent market valuations has prompted renewed scrutiny from income-oriented investors. Novo Nordisk’s stock decline over the last three years contrasted with Eli Lilly’s ascent, widening the valuation gap. Novo Nordisk traditionally allocates a portion of free cash flow to dividends, raising the question of whether the current share price represents an appealing entry point for those seeking reliable distributions.

Although dividend policies remain subject to board approval and earnings fluctuations, the company has historically maintained a payout ratio that leaves room for reinvestment in research and manufacturing. The resurgent prescription growth of the Wegovy pill could bolster cash generation, supporting both dividend stability and additional capacity expansion.

Outlook

Management has indicated that 2026 will be a transition year characterized by competitive pricing dynamics, regulatory adjustments, and supply-chain scaling. Nevertheless, the first-quarter performance of the oral Wegovy formulation demonstrates significant latent demand for GLP-1 therapies in pill form. Early data suggest that the pill is bringing new patients into the therapeutic category rather than diverting users from injections, a development that encourages expectations of sustained revenue growth.

Ongoing monitoring of prescription trends, manufacturing throughput, and regional pricing developments will be essential to assess whether Novo Nordisk can fully translate initial momentum into long-term market share gains. For now, the company’s ability to deliver 2 million prescriptions within weeks of launch underscores the commercial potential of an oral GLP-1 option and highlights a strategic pathway for Novo Nordisk to narrow the performance gap with its principal competitor.